StockData
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

10x Genomics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$69.89+0.03 (+0.04%)

Close on Oct 19, 2026

Market cap
$9.08B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026After market close$151.00M––
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026After market close$150.80M––
Q4 FY2025
Ended Dec 31, 2025
Jan 12, 2026During market hours$166.00M––
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025After market close$149.00M$-0.22–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025After market close$172.90M$0.28–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025After market close$154.90M$-0.28–
Q4 FY2024
Ended Dec 31, 2024
Jan 13, 2025Before market open$165.00M––
Q3 FY2024
Ended Sep 30, 2024
Oct 9, 2024After market close$151.70M––
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
Apr 30, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Jan 8, 2024Before market open–––

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
growth over full year 2025non-GAAPfull year 20262% to 5% growthNew
revenuefull year 2026$610.00M to $630.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements 10x Genomics filed with the SEC